Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +15.20p +0.91% 1,691.20p 1,694.80p 1,695.80p 1,702.20p 1,687.80p 1,692.60p 6,038,757 16:35:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,821.0 4,048.0 73.7 22.9 83,959

Glaxosmithkline Share Discussion Threads

Showing 19276 to 19300 of 20000 messages
Chat Pages: Latest  776  775  774  773  772  771  770  769  768  767  766  765  Older
DateSubjectAuthorDiscuss
14/2/2019
20:40
Tipped in IC tonight I understand
ayl30
14/2/2019
19:33
It happens Graham. Ten years ago on a CFD I accidentally bought £1m of gold on margin of 1%. I could have lost my shirt.
zicopele
14/2/2019
17:50
Who's for a tripple top at 1620 - good short from there?
toffeeman
14/2/2019
15:14
Me too. I've been badly underwater most of the time but it came right in the end and meanwhile there have been the dividends. I actually sold at 17 and bought back at 16, so at first I felt rather smug that come what may I couldn't have done the wrong thing. Then I realized I had bought 3 times as many as I sold so actually I was exposed.
grahamite2
14/2/2019
14:13
Been in this for 3 years, divi held up well in my opinion considering the overall market.
ma hee
14/2/2019
14:10
I like GSK dividend, but not increased for 4 years, thats why GSK ord shares like a bond for me.
montyhedge
14/2/2019
14:09
Wasn't that long ago when you were banging on about GSK's div Monty ..change like the weather :)
badtime
14/2/2019
12:16
Astra amazing results, their dividend won't be the same, like GSK has been for the last 4 years, 80p.
montyhedge
14/2/2019
11:55
"Anyone who examines the incidence of failure of drugs in phase three clinical trials knows that even after 10-15 years of development,a drug can come to nought in the latter stages.Patent protection is key to new drug development.If you don’t want new drugs,then fine just allow governments to radically reduce the return on capital by interfering in the current system" Indeed. Spot on. Apparently each drug costs up to £1bn to develop and take through to phase 3 trials where even then they often fail on the efficacy front. Expensive. Patents there to ensure drug companies recoup their losses on the 8-9/10 that never pass phase 3.
wbecki
14/2/2019
11:55
What GSK would give for AZN results which are quite spectacular.
zicopele
14/2/2019
02:10
A dilemma for all governments wishing to control cost of healthcare.Both democrats and republicans are increasingly favouring the increased use of generics as soon as proprietary patents expire but there’s nothing new here.Anyone who examines the incidence of failure of drugs in phase three clinical trials knows that even after 10-15 years of development,a drug can come to nought in the latter stages.Patent protection is key to new drug development.If you don’t want new drugs,then fine just allow governments to radically reduce the return on capital by interfering in the current system.In some instances,the amount charged for certain medication is morally indefensible but such instances are not widespread and are normally “shamed” in the media.Drug companies will be making a very good return on capital for the foreseeable future. Where drug companies are open to criticism was adroitly identified by Hilary Clinton.Drug companies might spend 25% odd of turnover on R&D but they also spend a considerable amount of money on marketing including “jollies”; for the medical profession,bribery of sorts.This is the sort of exercise which should be penalised.
steeplejack
13/2/2019
18:06
There's a detailed SA article on their main oncology compound for anyone interested. It's above my pay grade, just about understand the concept.
essentialinvestor
13/2/2019
16:29
Yes clamp down coming, margins squeezed.
montyhedge
13/2/2019
16:24
Americans pay 180 percent of what Europeans, Canadians, and Japanese pay for the exact same drugs! Our seniors aren't going to foot the bill for free-riders abroad any longer, HHS Secretary Alex Azar says. pic.twitter.com/Zj3Bk8lsdE
wbecki
13/2/2019
15:55
Sold GSK 1560p pick up at 1465p after ex div, piled into IAG (British Airways) no stamp duty only three stocks in FTSE 100 no stamp duty.
montyhedge
13/2/2019
15:52
GSK can now spend the time spent on Advair on shingles.
abdullla
13/2/2019
15:49
You always plan for success. ;)
alphorn
13/2/2019
15:45
They must have manufactured stock before the final audit ….. ;o)
tradermichael
13/2/2019
15:43
Mylan must have been ready to distribute that generic Advair. 70% discount, GSK can compete surely.
montyhedge
13/2/2019
14:04
The oncology assets are key to their longer term success. Short term headwind is potentially a stronger GBP on the back of any BREXIT resolution. Appreciate that's not a very popular view atm, however think the upside to GBP v USD and in particular EURO, is being underestimated.
essentialinvestor
13/2/2019
13:31
Happy to hold
badtime
13/2/2019
08:35
It’s not going to be easy to convince the market that Glaxo’s outlook is markedly improving.Glaxo was the darling of the 1980s and 90s on the back of Zantacs explosive growth supplemented by Ventolin and Fortam.By the turn of the millennium,the best was discounted as the company merged with SKB.The price back then briefly moved up to the low 20 pounds but has been arguably under pressure ever since.When the company is forecasting an earnings decline this year,it takes a bit of faith to look further to earnings progression.Jeffries target price of £17-50 owes as much to the yield support as to any conviction that the company is set to enjoy a burst of growth.To use old parlance,i think Glaxo could be termed a “weak buy”. Nonetheless,i’m surprised that Glaxo doesn’t react more positively to Jeffries recommendation.Probably ran it up last week in expectation.There217;s always been a lot of arbitrage play between the ordinary and the ADRs here.The market-makers like nothing better than to hoover up stock here and sell it out in New York and vicerversa for a quick turn.
steeplejack
13/2/2019
07:47
I (for one) am optimistic …. that's why I keep buying GSK !!
tradermichael
13/2/2019
05:58
Glaxo: reinvigorated pipeline can support bumper divi The pipeline at GlaxoSmithKline (GSK) has been ‘reinvigorated’ and Jefferies says the model that allows it to pay the highest dividend in the EU large-cap pharmaceutical space is sustainable. Analyst Peter Welford reiterated his ‘buy’ recommendation and target price of £17.50 on the stock after raising his earnings per share estimate by 7%. The shares were trading at £15.53 yesterday. ‘GSK offers the highest dividend yield of EU large-cap pharma, which our model suggests is sustainable… at least until the proposed split of the consumer healthcare joint venture,’ he said. ‘We see the strategic rationale for a UK demerger within three years as an opportunity to crystallise value, plus consumer standalone can support higher debt levels.’ Welford said the recent £4 billion acquisition of Tesaro did boost the group’s oncology pipeline and the cancer specialism would ‘prove critical’ but even so he was ‘not enamoured by the deal’. Https://citywire.co.uk/funds-insider/news/the-expert-view-glaxosmithkline-debenhams-and-domino-s/a1200090?re=62137&ea=254058&utm_source=BulkEmail_FundsInsider+DawnChorus&utm_medium=BulkEmail_FundsInsider+DawnChorus&utm_campaign=BulkEmail_FundsInsider+DawnChorus#i=2 If nothing else it's a change from the ceaseless pessimism here.
grahamite2
12/2/2019
18:02
Quite right Dr. A lot of the goodness has now gone.
zicopele
Chat Pages: Latest  776  775  774  773  772  771  770  769  768  767  766  765  Older
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190826 07:07:13